These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30702955)

  • 21. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Aihara M; Kano Y; Fujita H; Kambara T; Matsukura S; Katayama I; Azukizawa H; Miyachi Y; Endo Y; Asada H; Miyagawa F; Morita E; Kaneko S; Abe R; Ochiai T; Sueki H; Watanabe H; Nagao K; Aoyama Y; Sayama K; Hashimoto K; Shiohara T;
    J Dermatol; 2015 Aug; 42(8):768-77. PubMed ID: 25982480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies.
    Lin CC; Chen CB; Wang CW; Hung SI; Chung WH
    Expert Rev Clin Immunol; 2020 Apr; 16(4):373-387. PubMed ID: 32154748
    [No Abstract]   [Full Text] [Related]  

  • 23. Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature.
    Wang R; Zhong S; Tu P; Li R; Wang M
    Dermatol Ther; 2019 Jul; 32(4):e12832. PubMed ID: 30659711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Sato S; Kanbe T; Tamaki Z; Furuichi M; Uejima Y; Suganuma E; Takano T; Kawano Y
    Pediatr Int; 2018 Aug; 60(8):697-702. PubMed ID: 29888432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pediatric Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Halted by Etanercept.
    Gavigan GM; Kanigsberg ND; Ramien ML
    J Cutan Med Surg; 2018; 22(5):514-515. PubMed ID: 29421925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome.
    Yamane Y; Matsukura S; Watanabe Y; Yamaguchi Y; Nakamura K; Kambara T; Ikezawa Z; Aihara M
    Allergol Int; 2016 Jan; 65(1):74-81. PubMed ID: 26666483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mechanisms of Severe Cutaneous Adverse Reactions and a New Treatment Strategy].
    Saito Y; Nakamura R
    Yakugaku Zasshi; 2019; 139(12):1557-1562. PubMed ID: 31787645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options.
    Worswick S; Cotliar J
    Dermatol Ther; 2011; 24(2):207-18. PubMed ID: 21410610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclosporine for SJS/TEN: a case series and review of the literature.
    Reese D; Henning JS; Rockers K; Ladd D; Gilson R
    Cutis; 2011 Jan; 87(1):24-9. PubMed ID: 21323097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children: 20 years study in a tertiary care hospital.
    Techasatian L; Panombualert S; Uppala R; Jetsrisuparb C
    World J Pediatr; 2017 Jun; 13(3):255-260. PubMed ID: 27650525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: A case report and published work review.
    Wang F; Gao X; Chen X; Tang X; Chen H; Han J
    J Dermatol; 2019 Nov; 46(11):1035-1038. PubMed ID: 31436331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Ng QX; De Deyn MLZQ; Venkatanarayanan N; Ho CYX; Yeo WS
    J Inflamm Res; 2018; 11():135-142. PubMed ID: 29636627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Valeyrie-Allanore L; Wolkenstein P; Brochard L; Ortonne N; Maître B; Revuz J; Bagot M; Roujeau JC
    Br J Dermatol; 2010 Oct; 163(4):847-53. PubMed ID: 20500799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Khalili B; Bahna SL
    Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Like Lupus Erythematosus.
    Tankunakorn J; Sawatwarakul S; Vachiramon V; Chanprapaph K
    J Clin Rheumatol; 2019 Aug; 25(5):224-231. PubMed ID: 29912772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new case series on etanercept treatment for toxic epidermal necrolysis.
    Paradisi A; Abeni D; Didona D; Ricci F; Canzona F; Didona B
    Eur J Dermatol; 2020 Oct; 30(5):561-568. PubMed ID: 33021477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TNF-α‒Mediated Keratinocyte Expression and Release of Matrix Metalloproteinase 9: Putative Mechanism of Pathogenesis in Stevens‒Johnson Syndrome/Toxic Epidermal Necrolysis.
    Olsson-Brown A; Yip V; Ogiji ED; Jolly C; Ressel L; Sharma A; Bergfeld W; Liu X; Khirwadkar N; Bellon T; Dickinson A; Ahmed S; Langton A; Watson R; Pirmohamed M; Carr DF
    J Invest Dermatol; 2023 Jun; 143(6):1023-1030.e7. PubMed ID: 36581093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis in a cohort of patients.
    Ao S; Gao X; Zhan J; Ai L; Li M; Su H; Tang X; Chu C; Han J; Wang F
    J Am Acad Dermatol; 2022 Jun; 86(6):1236-1245. PubMed ID: 35121075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome/toxic epidermal necrolysis: A proteomics analysis from two prospective cohorts.
    Gong T; Zhang P; Ruan SF; Xiao Z; Chen W; Lin M; Zhong Q; Luo R; Xu Q; Peng J; Cheng B; Chen F; Chen L; Chung WH; Ji C
    J Am Acad Dermatol; 2023 Jul; 89(1):45-52. PubMed ID: 36963506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.